Aromatase Inhibitors for Breast Cancer Treatment and Prevention
Author Information
Author(s): Fabian C J
Primary Institution: University of Kansas Medical Center
Hypothesis
Are aromatase inhibitors more effective than tamoxifen for treating hormone receptor-positive breast cancer?
Conclusion
Aromatase inhibitors are now preferred for treating hormone receptor-positive breast cancer in postmenopausal women and show promise in prevention.
Supporting Evidence
- Aromatase inhibitors have largely replaced tamoxifen as the preferred treatment for hormone receptor-positive breast cancer.
- Adverse events associated with both drug classes are manageable.
- Current studies are testing AIs for breast cancer prevention in high-risk women.
Takeaway
Aromatase inhibitors help treat breast cancer by blocking estrogen, which can fuel cancer growth. They are often better than older treatments like tamoxifen.
Methodology
Expert opinion based on review of literature on relevant clinical trials.
Potential Biases
The author has received funding from pharmaceutical companies, which may influence the findings.
Limitations
The study primarily focuses on postmenopausal women and may not apply to premenopausal women.
Participant Demographics
Postmenopausal women with hormone receptor-positive breast cancer.
Statistical Information
P-Value
0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website